Washington, DC, July 14 2025 – Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects
Under the direction of CEO Benjamin Holmes, Nanochon, Inc. is set to revolutionize the treatment of cartilage loss and damage. The company’s Chondrograft™ implant, a
LaunchPort is pleased to announce that Nanochon has joined their City Garage/Baltimore Peninsula location as a LaunchPort Resident. “Over the last three years, Nanochon has
LOS ANGELES-MedTech Innovator, the world’s largest accelerator of medical technology companies, today announced its 2024 Accelerator Cohort. After a competitive selection process with a five percent
WASHINGTON–Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The
Founded in 2016, Nanochon aims to facilitate cartilage replacement and repair for patients suffering from knee injuries. It relies on 3D printing technology, specifically extrusion,
Grand Rapids, Mich., November 27, 2023 — cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today
Chondrograft™ is not approved yet for marketing.
Sign up with your email address to receive news and updates.
Disclaimer: The images displayed on this website include artistic illustrations and graphical representations which are intended to provide a general sense of the subject matter.
